CNTG Centogene

Collaboration Between CENTOGENE and U-Diagnostics Increases COVID-19 Testing Capacities in the Netherlands

Collaboration Between CENTOGENE and U-Diagnostics Increases COVID-19 Testing Capacities in the Netherlands
EN
14/10/2020

Underlying

CNTGCentogene

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Centogene

 PRESS RELEASE
Free
CNTG CENTOGENE

CENTOGENE Closes Strategic Transaction with Private Equity Group Charm...

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”) today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited (“Charme”). As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE’s sole operating subsidiary, certain intercompany receivabl...

March 12, 2025 1 EN
 PRESS RELEASE
Free
CNTG CENTOGENE

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CENTOGENE Announces Voting Results of Extraordinary General Meeting Approval of All Resolutions, Including Announced Transaction With Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the previously announced envisag...

December 5, 2024 1 EN
 PRESS RELEASE
Free
CNTG CENTOGENE

CENTOGENE Signs Strategic Transaction With Private Equity Group Charme...

CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement (“SPA”) pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited (“Charme”), a pan-European private eq...

November 13, 2024 1 EN
 PRESS RELEASE
Free
CNTG CENTOGENE

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in...

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in ...

September 25, 2024 1 EN
 PRESS RELEASE
Free
CNTG CENTOGENE

CENTOGENE Receives Delisting Notice From Nasdaq

CENTOGENE Receives Delisting Notice From Nasdaq CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq. The notice indicates that CENTOGENE (the “Company”) remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million mark...

August 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch